A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year
A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year
复制标题
米托蒽醌治疗多发性硬化症的对照试验：一年的系列 MRI 评估
DOI：
10.1017/s0317167100041263
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
M. Prencipe
中科院分区：
文献类型：
--
作者：
S. Bastianello;C. Pozzilli;F. D’Andrea;E. Millefiorini;M. Trojano;S. Morino;C. Gasperini;A. Bozzao;M. Gallucci;C. Andreula;L. Bozzao;D. Gambi;M. Prencipe
Abstract: We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p < 0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.
